ADIAL PHARMACEUTICALS INC (ADIL) Stock Price, Quote, News and Overview
NASDAQ:ADIL - Nasdaq - US00688A2050 - Common Stock - Currency: USD
ADIL Quote, Performance and Key Statistics
0.786
+0.02 (+2.21%)
The current stock price of ADIL is 0.786 USD. In the past month the price decreased by -19.8%. In the past year, price decreased by -4.73%.
ADIL Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About ADIL
Company Profile
Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. The company is headquartered in Charlottesville, Virginia and currently employs 4 full-time employees. The company went IPO on 2018-07-27. The firm is focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. AD04 is investigated in the Company’s ONWARD pivotal Phase III clinical trial for the treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company’s companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
Company Info
ADIAL PHARMACEUTICALS INC
1180 Seminole Trail, Suite 495
Charlottesville VIRGINIA 22901 US
CEO: William B. Stilley
Employees: 6
Company Website: https://www.adialpharma.com/
Investor Relations: https://ir.adialpharma.com/
Phone: 14344229800
ADIAL PHARMACEUTICALS INC / ADIL FAQ
What is the stock price of ADIAL PHARMACEUTICALS INC today?
The current stock price of ADIL is 0.786 USD. The price increased by 2.21% in the last trading session.
What is the ticker symbol for ADIAL PHARMACEUTICALS INC stock?
The exchange symbol of ADIAL PHARMACEUTICALS INC is ADIL and it is listed on the Nasdaq exchange.
On which exchange is ADIL stock listed?
ADIL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ADIAL PHARMACEUTICALS INC stock?
9 analysts have analysed ADIL and the average price target is 7.65 USD. This implies a price increase of 873.28% is expected in the next year compared to the current price of 0.786. Check the ADIAL PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ADIAL PHARMACEUTICALS INC worth?
ADIAL PHARMACEUTICALS INC (ADIL) has a market capitalization of 5.09M USD. This makes ADIL a Nano Cap stock.
How many employees does ADIAL PHARMACEUTICALS INC have?
ADIAL PHARMACEUTICALS INC (ADIL) currently has 6 employees.
What are the support and resistance levels for ADIAL PHARMACEUTICALS INC (ADIL) stock?
ADIAL PHARMACEUTICALS INC (ADIL) has a support level at 0.74 and a resistance level at 0.8. Check the full technical report for a detailed analysis of ADIL support and resistance levels.
Should I buy ADIAL PHARMACEUTICALS INC (ADIL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ADIL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ADIL, evaluating the profitability, health, valuation and growth aspects
- ADIAL PHARMACEUTICALS INC (ADIL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ADIAL PHARMACEUTICALS INC (ADIL) Sales and EPS estimates to see what analysts future expectations are.
- ADIAL PHARMACEUTICALS INC (ADIL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ADIAL PHARMACEUTICALS INC (ADIL) Insider and Institutional Ownership to learn about the owners and their transactions.
- ADIAL PHARMACEUTICALS INC (ADIL) Stock Chart to make your own analysis
- ADIAL PHARMACEUTICALS INC (ADIL) Latest news and press-releases to stay up to date.
Does ADIAL PHARMACEUTICALS INC (ADIL) stock pay dividends?
ADIL does not pay a dividend.
When does ADIAL PHARMACEUTICALS INC (ADIL) report earnings?
ADIAL PHARMACEUTICALS INC (ADIL) will report earnings on 2025-03-31, after the market close.
What is the Price/Earnings (PE) ratio of ADIAL PHARMACEUTICALS INC (ADIL)?
ADIAL PHARMACEUTICALS INC (ADIL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.94).
What is the Short Interest ratio of ADIAL PHARMACEUTICALS INC (ADIL) stock?
The outstanding short interest for ADIAL PHARMACEUTICALS INC (ADIL) is 0.95% of its float. Check the ownership tab for more information on the ADIL short interest.
ADIL Technical Analysis
ADIL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ADIL. The financial health of ADIL is average, but there are quite some concerns on its profitability.
ADIL Financial Highlights
Over the last trailing twelve months ADIL reported a non-GAAP Earnings per Share(EPS) of -2.94. The EPS increased by 48.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -194.36% | ||
| ROE | -221.75% | ||
| Debt/Equity | 0 |
ADIL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to ADIL. The Buy consensus is the average rating of analysts ratings from 9 analysts.